THERAPY DOSSIER · th-53d831f562b7

N-acetylserotonin (NAS)

Drug · No confident ChEMBL match; melatonin precursor, TrkB agonist (research)

Evidence & regulatory context

Mechanism: No confident ChEMBL match; melatonin precursor, TrkB agonist (research)
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23994834 ↗2013Reported benefit

Protective effect of N-acetylserotonin against acute hepatic ischemia-reperfusion injury in mice.

MouseIschaemia-reperfusionHepaticKunmingMalen = 18 mice in total, n = 6 per group across three groups (sham…Intraperitoneal5 mg/kg (preliminary work compared 5, 10 and 20 mg/kg; 20 m…30 min before induction of ischaemia (pre-treatment)

Model: Hepatic ischaemia-reperfusion produced by clamping the hepatic artery, portal vein and common bile duct with a microvascular bulldog clamp for 30 min followed by 6 h reperfusion

N-acetylserotonin preserved hepatic architecture, lowered the apoptosis index from 25.8 +/- 3.5% to 12.7 +/- 1.0% (sham 1.5 +/- 0.3%), reduced serum AST, reduced malondialdehyde from 2.4 +/- 0.5 to 1.4 +/- 0.2 nmol/mg protein, raised superoxide dismutase from 68.6 +/- 15.9 to 91.6 +/- 13.9 U/mg pro…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.

Loading the evidence…